Axial Biotherapeutics racks up $19.15 mln

Boston-based Axial Biotherapeutics, a newly launched biopharmaceutical company, has secured $19.15 million in Series A financing. Longwood Fund and Domain Associates led the round with participation from other investors that included Kairos Ventures and Heritage Medical Systems. In conjunction with the financing, Axial Biotherapeutics has named Dr. David H. Donabedian as CEO and board director.

North AmericaUSBriefs